Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 10, 2013, Pages 1525-1527

  Togami, Kohei ^a,b   Kanehira, Yukimune ^b   Tada, Hitoshi ^a,b  

^a HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

^b OHU UNIVERSITY   (Japan)

Author keywords

5 carboxypirfenidone; 5 hydroxypirfenidone; Idiopathic pulmonary fibrosis; Lung fibroblast; Pirfenidone

Indexed keywords

5 CARBOXYPIRFENIDONE; 5 HYDROXYPIRFENIDONE; ANTIFIBROTIC AGENT; COLLAGEN; HYDROXYPROLINE; PIRFENIDONE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL LEVEL; COLLAGEN SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG SCREENING; FIBROSING ALVEOLITIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; RAT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE; COLLAGEN; FIBROBLASTS; HUMANS; HYDROXYPROLINE; IDIOPATHIC PULMONARY FIBROSIS; LUNG; PYRIDONES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84887117377     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00452     Document Type: Article

References (16)

1. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N. Engl. J. Med., 345, 517-525 (2001). (Pubitemid 32758505)
2. Adamali HI, Maher TM. Current and novel drug therapies for idio pathic pulmonary fibrosis. Drug Des. Devel. Ther., 6, 261-272 (2012).
3. Peng ZZ, Hu GY, Shen H, Wang L, Ning WB, Xie YY, Wang NS, Li BX, Tang YT, Tao LJ. Fluorofenidone attenuates collagen I and transforming growth factor-beta1 expression through a nicotinamide adenine dinucleotide phosphate oxidase-dependent way in NRK- 52E cells. Nephrology (Carlton), 14, 565-572 (2009).
4. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther., 291, 367-373 (1999). (Pubitemid 29451612)
5. Zhao XY, Zeng X, Li XM, Wang TL, Wang BE. Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells. Clin. Exp. Pharmacol. Physiol., 36, 963-968 (2009).
6. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br. J. Pharmacol., 133, 687-694 (2001). (Pubitemid 32642874)
7. Rubino CM, Bhavnani SM, Ambrose PG, Forrest A, Loutit JS. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm. Pharmacol. Ther., 22, 279-285 (2009).
8. Taniyama M, Ohbayashi S, Narita M, Nakazawa R, Hasegawa S, Azuma N, Teraoka S, Ota K, Yamauchi S, Margolin SB. Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients. Eur. J. Clin. Pharmacol., 52, 77-78 (1997). (Pubitemid 27168216)
9. Huang NY, Ding L, Wang J, Zhang QY, Liu X, Lin HD, Hua WY. Pharmacokinetics, safety and tolerability of pirfenidone and its major metabolite after single and multiple oral doses in healthy Chinese subjects under fed conditions. Drug Res., 63, 388-395 (2013).
10. Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J. Pharmacokinet. Biopharm., 6, 547-558 (1978).
11. Hutson PR, Crawford ME, Sorkness RL. Liquid chromatographic determination of hydroxyproline in tissue samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 791, 427-430 (2003). (Pubitemid 36638776)
12. Wang Y, Zhao X, Zhong J, Chen Y, Liu X, Wang G. Simple determination of pirfenidone in rat plasma via high-performance liquid chromatography. Biomed. Chromatogr., 20, 1375-1379 (2006). (Pubitemid 46099744)
13. Nakayama S, Mukae H, Sakamoto N, Kakugawa T, Yoshioka S, Soda H, Oku H, Urata Y, Kondo T, Kubota H, Nagata K, Kohno S. Pirfenidone inhibits the expression of HSP47 in TGF-β1-stimulated human lung fibroblasts. Life Sci., 82, 210-217 (2008).
14. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am. J. Physiol., 276, L311-L318 (1999). (Pubitemid 29102273)
15. Gan Y, Herzog EL, Gomer RH. Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther. Clin. Risk Manag., 7, 39-47 (2011).
16. Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur. Respir. J., 30, 835-839 (2007). (Pubitemid 351194784)